Articles

Find an Article

Filter articles

Applied Filters

Showing 61 to 70 of 143 results

LSIPR 50 2016: Robert Langer

US05-10-2016

Robert Langer was selected in the LSIPR 50 2016 publication for his influence on the life sciences industry. Langer was featured in the business and innovation section, as LSIPR reports.

Preview: Life Sciences IP Summit 2016

EU16-09-2016Sarah Porch

Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC.

Drug price regulation in Brazil: Roche faces IP rights abuse claims

Brazil02-08-2016Anderson Ribeiro and Ricardo Campello

The Brazilian Federal Prosecutor’s Office has taken court action against Roche for allegedly abusing IP rights in its sales of Herceptin to state governments. Anderson Ribeiro and Ricardo Campello of Provedel Advogados analyse the case.

Under surveillance: generic and biosimilar MAs

EU26-07-2016Ruth Franken

In order to be well prepared before a generic or biosimilar marketing authorisation is approved, drugs companies in the EU may consider monitoring pending applications, says Ruth Franken of Hogan Lovells.

From the EU to Australia: latest SPC developments

Australia, EU07-07-2016Gareth Morgan

Legislative developments surrounding supplementary protection certificates in the EU are moving fast, and may be catching on as far afield as Australia. Gareth Morgan of Olswang explains more.

Brexit and IP: business as usual, for now

EU, UK07-07-2016Claire Phipps-Jones

Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows.

Breathing life into patents

US07-06-2016MaryAnne Armstrong

Applicants wishing to extend their patents’ term of protection do not have to necessarily match up the wording of the claims and the label of the relevant drug for there to be infringement by an ANDA, as MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch reports.

Greater convergence: IP and competition law

Russia03-06-2016Ilya Goryachev

In Russia, more attention is being paid towards the correlation between IP rights and competition restrictions, and pharma companies should keep abreast of developments, says Ilya Goryachev of Gorodissky & Partners.

What Canada can learn from SPCs in Europe

Canada, EU21-04-2016Shirley Liang

Unlike in the EU, Canada does not have additional pharma patent protection to compensate for regulatory delays, but that looks set to change, as Shirley Liang, an IP lawyer in Canada, explains.

Avoiding the Actavis SPC trap

International09-03-2016David Carling and Michael Pears

The UK Intellectual Property Office has issued a favourable decision on an SPC for an “innovative” combination product. David Carling and Michael Pears of Potter Clarkson explain the reasoning and examine its implications.

Showing 61 to 70 of 143 results

LSIPR